Staffan Encrantz Biography and Net Worth

Director of Sight Sciences


Founder and Chairman of Allegro Investment Fund, L.P., a registered Cayman Islands Investment Fund that is managed by Allegro Investment Inc. Located in Menlo Park, CA, Allegro primarily invests in growth stage private companies and supports its portfolio by providing growth capital as well as strategic, operating and financial expertise.
Mr. Encrantz has actively led investments in and operation of a variety of companies for over 30 years. He has led the growth and development of both early stage companies and established businesses in a wide variety of fields.
Mr. Encrantz is currently Chairman of AnaMar AB, ClosingCorp Inc, Evolve Controls, LLC, Nclear Inc, Alestra Ltd., Koncentra Holding AB and the Koncentra Verkstads AB group. He is also a director of GovX, Inc, Oxymetal SAS and several other companies.

Mr. Encrantz previously worked at ASEA AB, Sweden (now ABB Ltd.), as its deputy General Counsel 1979-1981, as Finance Manager 1981-1984, and during 1984-1990 in Switzerland and the UK as Business Area manager responsible for ABB’s Commodity Trading and Counter Trading group. Prior to this, he worked at Skandia Insurance Co, Sweden as its General Counsel and in private law practice.

Mr. Encrantz holds a law degree (Magna cum Laude) from Uppsala University, Sweden.

What is Staffan Encrantz's net worth?

The estimated net worth of Staffan Encrantz is at least $4.51 million as of November 29th, 2023. Mr. Encrantz owns 871,373 shares of Sight Sciences stock worth more than $4,513,712 as of March 28th. This net worth evaluation does not reflect any other investments that Mr. Encrantz may own. Learn More about Staffan Encrantz's net worth.

How do I contact Staffan Encrantz?

The corporate mailing address for Mr. Encrantz and other Sight Sciences executives is 4040 CAMPBELL AVE SUITE 100, MENLO PARK CA, 94025. Sight Sciences can also be reached via phone at 877-266-1144 and via email at [email protected]. Learn More on Staffan Encrantz's contact information.

Has Staffan Encrantz been buying or selling shares of Sight Sciences?

Staffan Encrantz has not been actively trading shares of Sight Sciences in the last ninety days. Most recently, on Wednesday, November 29th, Staffan Encrantz bought 3,223 shares of Sight Sciences stock. The stock was acquired at an average cost of $3.50 per share, with a total value of $11,280.50. Following the completion of the transaction, the director now directly owns 871,373 shares of the company's stock, valued at $3,049,805.50. Learn More on Staffan Encrantz's trading history.

Who are Sight Sciences' active insiders?

Sight Sciences' insider roster includes Staffan Encrantz (Director), and Jesse Selnick (CFO). Learn More on Sight Sciences' active insiders.

Are insiders buying or selling shares of Sight Sciences?

In the last year, Sight Sciences insiders bought shares 7 times. They purchased a total of 521,854 shares worth more than $1,459,475.22. In the last year, insiders at the sold shares 5 times. They sold a total of 2,881,348 shares worth more than $16,864,180.88. The most recent insider tranaction occured on January, 17th when CEO Paul Badawi sold 15,917 shares worth more than $82,131.72. Insiders at Sight Sciences own 27.1% of the company. Learn More about insider trades at Sight Sciences.

Information on this page was last updated on 1/17/2024.

Staffan Encrantz Insider Trading History at Sight Sciences

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/29/2023Buy3,223$3.50$11,280.50871,373View SEC Filing Icon  
11/27/2023Buy246,331$3.31$815,355.61614,481View SEC Filing Icon  
11/24/2023Buy21,855$3.09$67,531.95368,150View SEC Filing Icon  
11/22/2023Buy41,085$2.50$102,712.50346,295View SEC Filing Icon  
11/20/2023Buy79,234$2.25$178,276.50236,733View SEC Filing Icon  
11/17/2023Buy126,664$2.19$277,394.16157,499View SEC Filing Icon  
11/14/2023Buy3,462$2.00$6,924.0030,496View SEC Filing Icon  
5/16/2022Buy300,000$8.20$2,460,000.00301,802View SEC Filing Icon  
5/13/2022Buy1,802$7.98$14,379.961,802View SEC Filing Icon  
12/1/2021Buy214,606$22.40$4,807,174.40View SEC Filing Icon  
11/29/2021Buy86,454$18.85$1,629,657.90View SEC Filing Icon  
10/18/2021Buy527,048$24.00$12,649,152.00View SEC Filing Icon  
See Full Table

Staffan Encrantz Buying and Selling Activity at Sight Sciences

This chart shows Staffan Encrantz's buying and selling at Sight Sciences by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Sight Sciences Company Overview

Sight Sciences logo
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.
Read More

Today's Range

Now: $5.18
Low: $5.05
High: $5.22

50 Day Range

MA: $4.57
Low: $4.02
High: $5.89

2 Week Range

Now: $5.18
Low: $1.04
High: $11.20

Volume

82,158 shs

Average Volume

146,217 shs

Market Capitalization

$256.67 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.76